Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

NowPatient vs Teleios Health

NowPatient
Graded #217

Higher grade

vs+5.299999999999997
Teleios Health
Graded #327

Lower grade

The verdict

NowPatient takes it — 65.5/100 to 60.2/100.

NowPatient grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NowPatient is a US-UK telehealth platform offering brand-name GLP-1 weight management access including Mounjaro, Wegovy (injection and oral tablet), and Saxenda.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueTeleios Health +49
35
84
Dose & formulationNowPatient +29
93
64
Clinical oversightNowPatient +37
86
49
Labs & monitoringNowPatient +6
54
48
FulfillmentNowPatient +28
70
42
Contract termsEven
55
55
NowPatient · left barTeleios Health · right bar

The numbers

MetricNowPatientTeleios Health
WeighScore65.5/10060.2/100
GradeCC
Scorecard rank#217#327
Semaglutide$1,349/mo (brand Wegovy)$99/mo (starting dose, compounded)
Tirzepatide$1,069/mo (brand Mounjaro, promotional rate)$139/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
NowPatient

Graded #217 · C

Strengths

  • Free telehealth consultation — you only pay for the medication
  • Brand-name Mounjaro, Wegovy injection, Wegovy oral tablet, and Saxenda all available
  • One of the few platforms offering Wegovy in both injection and oral pill form
  • No compounded options — every drug is FDA-approved brand-name

Where it loses points

  • Cash-pay pricing tracks full brand list price (~$1,000–$1,350/mo)
  • No compounded semaglutide or tirzepatide (usually the cheaper route)
  • State availability determined during intake, not shown upfront
  • Does not offer Foundayo (orforglipron)
Teleios Health

Graded #327 · C

Strengths

  • Compounded semaglutide from $99/mo — among the lowest floor prices in cash-pay telehealth
  • Compounded tirzepatide from a competitive $139/mo floor
  • Markets physician (MD/DO) prescribing rather than an NP-only model
  • Clean meta-tag and SEO implementation

Where it loses points

  • Single-page app: state availability, pharmacy partner, dose pricing, lab requirements, and refund policy aren't visible and couldn't be verified
  • No named medical director, physician, or corporate entity disclosed
  • Year founded unknown — a newer floor-price entrant warranting extra scrutiny
  • No LegitScript, NABP, or SOC 2 trust signal found
  • Heavy paid-acquisition ad-tech stack — pair with diligence on the clinical layer

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard